Item 2.02. Results of Operations and Financial Condition.

On November 27, 2012, Avanir Pharmaceuticals, Inc. issued a press release announcing preliminary, unaudited financial results for the three and twelve months ended September 30, 2012 and the initiation of a Phase I clinical trial for AVP-786 (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

99.1 Press Release, dated November 27, 2012

* * *

-2-

---